Efficacy of eletriptan in migraine-related functional impairment: Functional and work productivity outcomes

Headache

Volumn 47, Issue 5, 2007, Pages 673-682

  Silberstein, Stephen D ^a,e   Cady, Roger K ^b   Sheftell, Fred D ^c   Almas, Mary ^d   Parsons, Bruce ^d   Albert, Kenneth S ^d  

^a JEFFERSON HEADACHE CENTER   (United States)

^b HEADACHE CARE CENTER   (United States)

^c NEW ENGLAND CENTER FOR HEADACHE   (United States)

^d PFIZER INC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Eletriptan; Functional impairment; Functional response; Migraine; Multidimensional assessment

Indexed keywords

ELETRIPTAN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; PRODUCTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WORK DISABILITY;

ADULT; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OUTPATIENTS; PYRROLIDINES; QUESTIONNAIRES; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRYPTAMINES; WORK CAPACITY EVALUATION; WORKLOAD;

EID: 34248348634     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00633.x     Document Type: Article

References (33)

1. Leonardi M. Migraine and disability: WHO's work to measure functioning, disability and health and the Global Burden of Diseases Study. J Headache Pain. 2003 4 (suppl 1 S12 S17.
2. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994 34 : 337 343.
3. Stewart AL, Greenfield S, Hays RD, et al Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA. 1989 262 : 907 913.
4. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well being of headache patients: Measurement by the Medical Outcomes Study instrument. Headache. 1993 33 : 351 358.
5. Wells KB, Stewart A, Hays RD. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989 262 : 914 919.
6. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: Epidemiology and patterns of health care use. Neurology. 2002 58 : 885 894.
7. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 41 : 646 657.
8. Dahlöf CG, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia. 1995 15 : 31 36.
9. Linde M, Dahlöf CG. Attitudes and burden of disease among self-considered migraineurs - a nation-wide population-based survey in Sweden. Cephalalgia. 2004 24 : 455 465.
10. Kolotylo CJ, Broome ME. Predicting disability and quality of life in a community-based sample of women with migraine headache. Pain Manag Nurs. 2000 1 : 139 151.
11. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The economic burden of lost productivity due to migraine headache: A specific worksite analysis. J Occup Environ Med. 2002 44 : 523 529.
12. Hemp P. Presenteeism: At work - but out of it. Harv Bus Rev. 2004 82 : 49 58.
13. MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: The migraine and zolmitriptan evaluation (MAZE) survey - Phase III. Curr Med Res Opin. 2004 20 : 1143 1150.
14. Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ. The family impact of migraine: Population-based studies in the USA and UK. Cephalalgia. 2003 23 : 429 440.
15. Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care. 2004 10 : 313 320.
16. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999 159 : 813 818.
17. Gerth WC, Sarma S, Hu XH, Silberstein SD. Productivity cost benefit to employers of treating migraine with rizatriptan: A specific worksite analysis and model. J Occup Environ Med. 2004 46 : 48 54.
18. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992 2 : 67 76.
19. Berg J. Economic evidence in migraine and other headaches: A review. Eur J Health Econ. 2004 5 (suppl 1 S43 S54.
20. Davies GM, Santanello N, Gerth W, Lerner D, Block GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia. 1999 19 : 497 502.
21. Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics. 2000 18 : 557 566.
22. Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer MS. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia. 2000 20 : 830 834.
23. Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine. The Disability in strategies for Care (DISC) study. Pharmacoeconomics. 2002 20 : 91 100.
24. Schulman EA, Cady RK, Henry D, et al Effectiveness of sumatriptan in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2000 75 : 782 789.
25. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998 158 : 1013 1018.
26. Farmer K, Cady R, Bleiberg J, et al Sumatriptan nasal spray and cognitive function during migraine: Results of an open-label study. Headache. 2001 41 : 377 384.
27. Tfelt-Hansen P, Block G, Dahlöf C, et al Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000 20 : 765 786.
28. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia. 2005 25 : 735 742.
29. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004 24 (suppl 1 9 160.
30. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ : Lawrence Earlbaum Associates 1988.
31. Holmes WF, MacGregor EA, Sawyer JP, Lipton RB. Information about migraine disability influences physicians' perceptions of illness severity and treatment needs. Headache. 2001 41 : 343 350.
32. McCracken LM, Iverson GL. Predicting complaints of impaired cognitive functioning in patients with chronic pain. J Pain Symptom Manage. 2001 21 : 392 396.
33. Marvel CL, Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am. 2004 27 : 19 36.